摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2(R)-benzyl-3-(N-benzyl-N-methylaminocarbonyl)propionic acid | 125016-13-9

中文名称
——
中文别名
——
英文名称
2(R)-benzyl-3-(N-benzyl-N-methylaminocarbonyl)propionic acid
英文别名
(2R)-2-benzyl-4-[benzyl(methyl)amino]-4-oxobutanoic acid
2(R)-benzyl-3-(N-benzyl-N-methylaminocarbonyl)propionic acid化学式
CAS
125016-13-9
化学式
C19H21NO3
mdl
——
分子量
311.381
InChiKey
UZCWKCXCHCCITJ-QGZVFWFLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    23
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    57.6
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    (2S,4S,5S)-5-[N-(t-butoxycarbonyl)-3-(4-thiazolyl)-L-alanyl]amino-N-butyl-6-cyclohexyl-4-hydroxy-2-isopropylhexanamide 、 2(R)-benzyl-3-(N-benzyl-N-methylaminocarbonyl)propionic acid 以to afford 187 mg of the title compound as a white powder, melting at 155°-156° C.的产率得到(2S,4S,5S)-5-{N-[2(R)-benzyl-3-(N-benzyl-L-methylaminocarbonyl)propionyl]-3-(4-thiazolyl)-L-alanyl}amino-N-butyl-6-cyclohexyl-4-hydroxy-2-isopropylhexanamide
    参考文献:
    名称:
    Peptides having renin inhibitory activity, their preparation and use
    摘要:
    式(I)的化合物:##STR1## [其中:R.sup.1是具有5或6个环原子的杂环基团,或--NR.sup.7R.sup.8,其中R.sup.7是烷基,R.sup.8是可选择取代的苯基,可选择取代的苯基烷基或环烷基;R.sup.2是可选择取代的苯基或萘基;R.sup.3是噻唑基;R.sup.4是环己基或异丙基;R.sup.5是烷基;R.sup.6是烷基]及其盐具有抑制肾素的活性,因此具有降压作用,并且对于由肾素-血管紧张素系统失调引起的高血压的诊断和治疗具有价值。它们可以通过反应适当的氨基酸或其衍生物制备得到。
    公开号:
    US05378689A1
  • 作为产物:
    描述:
    3-[2(R)-benzyl-4-(N-benzyl-N-methylamino)-4-oxobutyryl]-4(R)-isopropyl-2-oxazolidinone 在 lithium hydroxide 、 sodium hydroxide 作用下, 以 四氢呋喃 为溶剂, 生成 2(R)-benzyl-3-(N-benzyl-N-methylaminocarbonyl)propionic acid
    参考文献:
    名称:
    Peptides having renin inhibitory activity, their preparation and use
    摘要:
    化合物的化学式(I):##STR1## [其中:R.sup.1是具有5个或6个环原子的杂环基团,或--NR.sup.7 R.sup.8,其中R.sup.7是烷基,R.sup.8是可选择取代的苯基,可选择取代的苯基烷基或环烷基;R.sup.2是可选择取代的苯基或萘基;R.sup.3是噻唑基;R.sup.4是环己基或异丙基;R.sup.5是烷基;R.sup.6是烷基]及其盐具有抑制肾素和因此降压活性,并且对于诊断和治疗由肾素-血管紧张素系统失调引起的高血压具有价值。它们可以通过将适当的氨基酸或其衍生物反应在一起制备。
    公开号:
    US05378689A1
点击查看最新优质反应信息

文献信息

  • Renin-inhibitory oligopeptides, their preparation and use
    申请人:Sankyo Company, Limited
    公开号:US05364844A1
    公开(公告)日:1994-11-15
    Compounds of formula (I): ##STR1## A is a carbon-carbon bond or C.sub.1 -C.sub.3 alkylene; B is imino group or C.sub.1 -C.sub.2 alkylene; R.sup.1 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, heterocyclic or optionally substituted amino; R.sup.2 is optionally substituted phenyl or optionally substituted naphthyl; R.sup.3 is thiazolyl, isoxazolyl or imidazolyl; R.sup.4 is isopropyl or cyclohexyl; R.sup.5 and R.sup.6 are C.sub.1 -C.sub.4 alkyl, or, together with the carbon atom to which they are attached, C.sub.3 -C.sub.7 cycloalkyl; R.sup.7 is hydrogen, optionally substituted C.sub.1 -C.sub.6 alkyl group; and R.sup.8 is hydrogen or C.sub.1 -C.sub.4 alkyl. These compounds have renin-inhibitory and, hence, hypotensive activities. The invention also provides a method for the treatment or prophylaxis of hypertension induced by failures in the renin-angiotensin system.
    式(I)的化合物: A是碳-碳键或C.sub.1 -C.sub.3烷基; B是亚胺基或C.sub.1 -C.sub.2烷基; R.sup.1是C.sub.1 -C.sub.4烷基,C.sub.1 -C.sub.4烷氧基,杂环或可选择取代的氨基; R.sup.2是可选择取代的苯基或可选择取代的萘基; R.sup.3是噻唑基,异噁唑基或咪唑基; R.sup.4是异丙基或环己基; R.sup.5和R.sup.6是C.sub.1 -C.sub.4烷基,或者与其连接的碳原子一起是C.sub.3 -C.sub.7环烷基; R.sup.7是氢,可选择取代的C.sub.1 -C.sub.6烷基; R.sup.8是氢或C.sub.1 -C.sub.4烷基。这些化合物具有抑制肾素的作用,因此具有降压活性。本发明还提供了一种治疗或预防由于肾素-血管紧张素系统功能障碍引起的高血压的方法。
  • Renin inhibitory oligopeptides, their preparation and use
    申请人:Sankyo Company Limited
    公开号:EP0326364A2
    公开(公告)日:1989-08-02
    Compounds of formula (I): [in which: A is a carbon-carbon bond or C1 - C3 alkylene; B is imino group or C1- C2 alkylene; R1 is C1- C4 alkyl, Ci - C4 alkoxy, heterocyclic or optionally substituted amino; R2 is optionally substituted phenyl or optionally substituted naphthyl; R3 is thiazolyl, isoxazolyl or imidazolyl; R4 is isopropyl or cyclohexyl; R5 and R6 are Ci - C4 alkyl, or, together with the carbon atom to which they are attached, C3- C7 cycloalkyl; R7 is hydrogen or optionally substituted C1- C6 alkyl; and R8 is hydrogen or Ci - C4 alkyl] have renin-inhibitory and, hence, hypotensive activities and are of value in the diagnosis and treatment of hypertension induced by failures in the renin-angiotensin system. They may be prepared by reacting together appropriate amino acids, lower oligopeptides or derivatives thereof.
    式(I)化合物: 其中A 是碳-碳键或 C1 - C3 亚烷基;B 是亚氨基或 C1 - C2 亚烷基;R1 是 C1 - C4 烷基、Ci - C4 烷氧基、杂环或任选取代的氨基;R2 是任选取代的苯基或任选取代的萘基;R3 是噻唑基、异噁唑基或咪唑基;R4 是异丙基或环己基;R5 和 R6 是 Ci - C4 烷基,或与所连接的碳原子一起是 C3 - C7 环烷基;R7 是氢或任选取代的 C1 - C6 烷基;以及 R8 是氢或 Ci - C4 烷基]。 具有肾素抑制活性,因此具有降血压活性,在诊断和治疗由肾素-血管紧张素系统故障引起的高血压方面具有价值。它们可通过将适当的氨基酸、低级寡肽或其衍生物反应在一起而制备。
  • Peptides having renin inhibitory activity their preparation and use
    申请人:Sankyo Company Limited
    公开号:EP0383635A2
    公开(公告)日:1990-08-22
    Compounds of formula (I): [in which: R1 is heterocyclic group having 5 or 6 ring atoms, or -NR7R8, where R7 is alkyl and R8 is optionally substituted phenyl, optionally substituted phenylalkyl or cycloalkyl; R2 is optionally substituted phenyl or naphthyl; R3 is thiazolyl; R4 is cyclohexyl or isopropyl; R5 is alkyl; and R6 is alkyl] and salts thereof have renin-inhibitory and, hence, hypotensive activities and are of value in the diagnosis and treatment of hypertension induced by failures in the renin-angiotensin system. They may be prepared by reacting together appropriate amino acids or derivatives thereof.
    式(I)化合物: 其中R1 是具有 5 或 6 个环原子的杂环基团,或 -NR7R8,其中 R7 是烷基,R8 是任选取代的苯基、任选取代的苯基烷基或环烷基;R2 是任选取代的苯基或萘基;R3 是噻唑基;R4 是环己基或异丙基;R5 是烷基;R6 是烷基]及其盐具有肾素抑制活性,因此具有降血压活性,在诊断和治疗由肾素-血管紧张素系统失效诱发的高血压方面具有价值。它们可通过将适当的氨基酸或其衍生物反应制备而成。
  • US5364844A
    申请人:——
    公开号:US5364844A
    公开(公告)日:1994-11-15
  • US5378689A
    申请人:——
    公开号:US5378689A
    公开(公告)日:1995-01-03
查看更多